Oct 29, 2024 · VALANX' novel protein conjugation platform. Through the power of synthetic biology and genetic code expansion we have developed a novel site-specific protein conjugation platform that allows precise control over conjugation site and number of conjugations on the protein of interest.

VALANX Biotech. was founded in 2017 as a spin-off of the Graz University of Technology. Our Mission. is to make the struggle of precise, reproducible protein conjugation a thing of the past, for the benefit of our partners, customers and patients. Our Vision

https://www.valanx.bio/wp-content/uploads/2024/10/animation-with-music.mp4 Genetic code expansion and synthetic amino acid incorporation Our technology completely frees up one codon of the genetic code to be used by our proprietary synthetic amino acid with no loss in expression system viability or yield.

Nov 7, 2023 · Put simply, VALANX uses innovative techniques from synthetic biology to offer creative solutions to a previously intractable problem for customers in the pharmaceutical industry and beyond. This opens new avenues for drug development.

Jun 5, 2024 · VALANX’ findings demonstrate the potential of VLX101, a novel Interleukin-2 conjugate and the efficacy of VALANX’ proprietary technology platform and therapeutic approach. Protein drugs hold great promise as therapeutics for a wide range of diseases however one of the greatest challenges is their short circulation half-life.

Gesellschaft mit beschränkter Haftung Limited Liability Company UID-Nr: ATU72234049 FN: FN 469177t Court of Jurisdiction: Klosterneuburg Rinnböckstraße 3, 2.

Oct 29, 2024 · Under the commercialization agreement, VALANX will produce ClickCRM using its upstream platform technology to incorporate its proprietary synthetic amino acid which harbors a unique chemical group for conjugation.

Gesellschaft mit beschränkter Haftung Limited Liability Company UID-Nr: ATU72234049 FN: FN 469177t Court of Jurisdiction: Klosterneuburg Rinnböckstraße 3, 2.

From December 4th to 6th, VALANX Biotech participated in the RESI London Pitch Challenge, hosted by Life Science Nation (LSN). This recognized event brought together innovative startups, investors, and licensing partners.

SOSV is a global venture capital firm providing multi-stage investment to develop and scale our founders' big ideas for positive change. VALANX' joined the SOSV portfolio through the IndieBio accelerator. www.sosv.com